With Interferon, Zydus Cadila Launches Third Salvo Against COVID-19

Vaccine Also Moving Towards Trials

Cadila Healthcare is evaluating the use of pegylated interferon alpha-2b to treat COVID-19 and will explore the possibility of approval in the US under the compassionate use program. This marks the company’s third front to fight the disease after hydroxychloroquine and a vaccine.

Runners_Blue_Background
Third Cadila Candidate Now In COVID-19 Race • Source: Shutterstock

After hydroxychloroquine and vaccines, Cadila Healthcare Ltd., the flagship firm of India's Zydus Cadila group, has opened a new front to tackle COVID-19 and is working on filing an investigational new drug application in the US for the use of pegylated interferon alpha-2b to treat the disease.

The company said a study conducted by the University of Texas Branch and another by a group of universities in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip